Written by the Nuvirox Research Team
Short answer: yes, with real but early evidence. Two separate human randomized controlled trials — one testing an NAD+ precursor combination, one testing plain nicotinamide — found reductions in liver inflammation markers in people with non-alcoholic fatty liver disease (NAFLD). This is one of the better-studied NAD+ health applications, though it's still early.
Key Points
- The liver's NAD+ pool is found to decline with age, which is linked to reduced fat-burning capacity and increased fat accumulation in liver cells.
- A 6-month RCT found NRPT (NR + pterostilbene) reduced markers of hepatic inflammation in 111 adults with NAFLD.
- A separate RCT found plain nicotinamide improved outcomes in diabetic patients with NAFLD specifically.
Why the liver is a logical target for NAD+ research
Non-alcoholic fatty liver disease (NAFLD) — now often called MASLD in updated terminology — develops when the liver's capacity to burn fat via beta-oxidation is outpaced by fat accumulating in liver cells, worsened by oxidative stress and inflammation. NAD+ is directly required for beta-oxidation to run, and it activates sirtuins that suppress the lipogenesis (fat-creation) pathways that contribute to fatty liver. Since human liver NAD+ has been found to deplete with age — partly because DNA-damage-activated enzymes called PARPs consume intracellular NAD+ — raising NAD+ availability is a mechanistically well-supported target for NAFLD specifically, more so than for many other conditions covered in NAD+ marketing.
Trial one: NRPT and hepatic inflammation
A 6-month, prospective, randomized, double-blind, placebo-controlled clinical trial tested daily NRPT (nicotinamide riboside plus pterostilbene, commercially known as Basis) in 111 adults with diagnosed NAFLD, across three arms: placebo, standard dose, and double dose. The trial found that NRPT reduced markers of hepatic inflammation compared to placebo, and the supplement was reported as safe and well tolerated across the 6-month period [1].
Study snapshot: NRPT and NAFLD — 6-month RCT
| Design | Randomized, double-blind, placebo-controlled, 3-arm |
| Population | 111 adults with diagnosed NAFLD |
| Dose / duration | NRPT standard or double dose, 6 months |
| Key finding | Reduced markers of hepatic inflammation vs. placebo |
Trial two: nicotinamide in diabetic NAFLD patients
A separate randomized controlled trial tested plain nicotinamide supplementation specifically in patients with both type 2 diabetes and NAFLD — a population where liver fat and metabolic dysfunction compound each other. The trial's rationale drew on the same biology: nicotinamide elevates hepatic NAD+, which activates sirtuin signaling that inhibits lipogenesis and promotes fatty acid oxidation, with earlier animal research showing nicotinamide riboside specifically improved glucose control and reduced hepatic steatosis [2]. This trial adds a second, independent line of human evidence in a population where liver and metabolic dysfunction overlap most.
Where the honest caveats are
Both trials measured inflammation markers and metabolic parameters rather than the harder outcomes that matter most for long-term liver health — biopsy-confirmed fibrosis regression, progression to cirrhosis, or liver-related mortality — which require much longer follow-up than either trial ran. Post-hoc analysis from an earlier, separate 12-week NR safety trial in obese men also suggested improvement in fatty liver, but that was a secondary, exploratory finding rather than the trial's primary design. This is real, converging evidence pointing in a consistent direction — but it's evidence of improved inflammatory markers over months, not proof of reversed liver disease over years.
What NAD+ won't do
NAD+ precursors are not a treatment for diagnosed liver disease, cirrhosis, hepatitis, or alcohol-related liver damage, and none of this research suggests using them in place of medical management for a diagnosed liver condition. If you have elevated liver enzymes, a NAFLD diagnosis, or any other liver concern, that's a conversation for your doctor — this research is relevant context for that conversation, not a substitute for it.
Frequently asked questions
Can NAD+ supplements help with fatty liver disease?
Two separate human RCTs found NAD+ precursors (NRPT and nicotinamide) reduced liver inflammation markers in people with NAFLD. It's genuinely promising, converging evidence, though longer trials measuring fibrosis or disease progression haven't been done yet.
Is this the same as treating cirrhosis or hepatitis?
No. These trials were in NAFLD/fatty liver specifically, not cirrhosis, hepatitis, or alcohol-related liver disease. Don't extrapolate this evidence to other liver conditions.
How long did the trials run?
The NRPT trial ran 6 months. That's long enough to see inflammation marker changes, but not long enough to measure harder outcomes like fibrosis reversal.
Should I stop other liver treatments if I start an NAD+ supplement?
No — talk to your doctor before making any changes to how you're managing a diagnosed liver condition. This research supports considering NAD+ precursors as a complementary approach, not a replacement for medical care.
For the metabolic side of liver health, our article on NAD+ and inflammation covers the broader anti-inflammatory research this liver evidence connects to, and if alcohol-related liver stress is part of your interest, see why alcohol makes you so tired the next day for the related metabolic burden alcohol places on the same pathways. Kidney health research follows a similar pattern of promise and honest limitation — see our companion piece on NAD+ and kidney health.
Were these NAFLD trial participants on other liver medications?
The trials didn't focus on drug interactions with other liver treatments; if you're on any prescribed liver-related medication, check with your doctor before adding an NAD+ supplement.
On dosing specifics: the NRPT NAFLD trial tested both a standard dose (250 mg NR + 50 mg pterostilbene daily) and a double dose (500 mg NR + 100 mg pterostilbene), which lets researchers begin to assess whether the hepatic inflammation benefit was dose-dependent — useful information for understanding whether "more" would be expected to help more, though the publicly summarized results don’t indicate a dramatically different response between the two arms. Both doses were reported as safe and well tolerated across the full 6-month trial period, which is a meaningful safety data point given how much longer this trial ran compared to most other NAD+ precursor human trials.
From Nuvirox
Why we formulated NAD+ Restore
If what you're dealing with sounds like it belongs in a doctor's office rather than a supplement aisle, please start there — a clinician can rule out the specific causes discussed above. For general cellular energy support, each serving of NAD+ Restore provides 500 mg of nicotinamide riboside chloride (NR), one of the two most-researched NAD+ precursors, within the dose range used in published human trials, alongside 150 mg trans-resveratrol and 50 mg quercetin (polyphenols studied alongside NAD+ pathways for cellular health support) and 10 mg of galactomannans from fenugreek to support absorption.
We back it with a 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
Learn more about NAD+ Restore →The bottom line
Liver health is genuinely one of the better-evidenced applications for NAD+ precursors in current human research — two independent randomized trials, in slightly different NAFLD populations, both found reduced inflammation markers. That's a real, converging signal. The honest limit is that both trials measured inflammation over months, not disease progression over years, so this supports cautious optimism rather than a confirmed disease-reversing effect.
References
- Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: a double-blind, placebo-controlled clinical trial. Hepatol Commun. 2022. PMID: 36082508.
- El-Kady RR, Ali AK, El Wakeel LM, Sabri NA, Shawki MA. Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial. Ther Adv Endocrinol Metab. 2022. doi:10.1177/20406223221077958.
- Conze D, Brenner C, Kruger CL. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Sci Rep. 2019;9:9772. doi:10.1038/s41598-019-46120-z.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.